Akari Therapeutics to Acquire 03 Life Sciences
Ticker: AKTX · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1541157
Sentiment: neutral
Topics: acquisition, pharmaceuticals, pipeline-expansion
Related Tickers: AKTX
TL;DR
Akari Therapeutics is buying 03 Life Sciences to boost its drug pipeline. Deal expected to close Q4 2025.
AI Summary
Akari Therapeutics Plc announced on September 26, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of 03 Life Sciences. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions. This acquisition aims to expand Akari's pipeline and therapeutic offerings.
Why It Matters
This acquisition could significantly expand Akari Therapeutics' drug pipeline and market presence in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks related to integration, regulatory approval, and market reception of combined products.
Key Players & Entities
- Akari Therapeutics Plc (company) — Acquiring company
- 03 Life Sciences (company) — Target company
- September 26, 2025 (date) — Date of agreement
- fourth quarter of 2025 (date) — Expected closing period
FAQ
What is the primary strategic rationale behind Akari Therapeutics' acquisition of 03 Life Sciences?
The acquisition is intended to expand Akari's pipeline and therapeutic offerings.
When is the acquisition of 03 Life Sciences expected to be completed?
The transaction is expected to close in the fourth quarter of 2025.
What are the conditions for the closing of the acquisition agreement?
The closing is subject to customary closing conditions.
What is the exact date of the report for this 8-K filing?
The date of the report is September 26, 2025.
What is the former name of Akari Therapeutics Plc?
Akari Therapeutics Plc was formerly known as Celsus Therapeutics Plc. and Morria Biopharmaceuticals PLC.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2025-09-29 17:00:56
Key Financial Figures
- $0.0001 — Market LLC Ordinary Shares, par value $0.0001 per share* N/A The Nasdaq Stock Mar
- $3 million — ng") for an aggregate purchase price of $3 million. The aggregate principal amount of the
- $3.8 million — st 2025 Notes issuable is approximately $3.8 million. On September 26, 2025, the Company c
- $312,500 — the August 2025 Notes Offering, issuing $312,500 aggregate principal amount of August 20
- $250,000 — otes for an aggregate purchase price of $250,000. Following this closing, the Company ha
Filing Documents
- form8-k.htm (8-K) — 36KB
- 0001493152-25-016039.txt ( ) — 239KB
- aktx-20250926.xsd (EX-101.SCH) — 4KB
- aktx-20250926_def.xml (EX-101.DEF) — 26KB
- aktx-20250926_lab.xml (EX-101.LAB) — 36KB
- aktx-20250926_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: September 29, 2025 By: /s/ Torsten Hombeck Name: Torsten Hombeck Title: Chief Financial Officer